Department of Public Affairs

3400 Spruce St.
Philadelphia, PA 19104-6021


Media Contact:

(for this release

Rebecca Harmon (215) 662-2560

March 6, 2003

GlaxoSmithKline Donates $10 Million To Support Research At the University of Pennsylvania School of Medicine

(March 6, 2003) -- GlaxoSmithKline (GSK) and the University of Pennsylvania School of Medicine announced today that GSK has provided Penn with an unrestricted grant of $10 million to support academic research.

"We at GSK are fortunate that the Delaware Valley, home to so many of our Research and Development staff, is also home to such a leading academic research center as the University of Pennsylvania," said Tachi Yamada, MD, Chairman, Research and Development, GSK. "We are hopeful that this grant will further the important research being done at Penn and facilitate scientific interchange between its scientists and our own. GSK and Penn are working towards a shared goal - increasing our understanding of human disease and finding new treatments for the patients who need them."

"We are delighted to receive this grant and look forward to exploring mutual scientific interests of Penn and GSK," said Dr. Arthur H. Rubenstein, Executive Vice President of the University of Pennsylvania for the Health System and Dean of the School of Medicine. "This generous grant will permit our researchers to continue to aggressively pursue the translational nature of our work - which seeks to transform knowledge gained at the benchside into safe and effective therapies and treatments that improve patient care."


Rebecca Harmon (215) 349-5660 rebecca.harmon@uphs.upenn.edu

Louise Dunn From U.S. 44-20-8047-5495 louise.a.dunn@gsk.com

Rick Koenig (610) 270 5546

GlaxoSmithKline (GSK) is one of the world's leading research-based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. The 18,000 people working in GSK's global R&D organization discover, develop, register, and support the commercialization of prescription medicines and vaccines for the treatment and prevention of human disease. In 2002 GSK invested $4 billion in research and development at more than 20 sites worldwide. GSK has R&D facilities in Philadelphia, Upper Merion, and Upper Providence, which employ 3,500 staff. GSK is a major funder of academic research in the US, with 378 active collaborations between US universities and GSK researchers. PENN Medicine is a $2.2 billion enterprise dedicated to the related missions of medical education, biomedical research, and quality patient care.

PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System (created in 1993 as the nation's first integrated academic health system). Today, Penn's School of Medicine is ranked #4 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools; and ranked #2 in the nation for receipt of NIH research funds. It supports 1400 full time faculty and 700 students, is recognized world-wide for its superior education and training of the next generation of physician/scientists and leaders of academic medicine. Penn's Health System consists of four wholly-owned hospitals (including its flagship Hospital of the University of Pennsylvania, rated one of the nation's top "Honor Roll" hospitals by U.S. News & World Report); a faculty practice plan; a primary-care provider network; three multispecialty satellite facilities; and home healthcare, hospice and long-term care.

# # #





Press Releases




Events & Calendars



Privacy Policy Disclaimer Terms of Use